10-Q quarterly report · filed Nov 5, 2026

Voyager Therapeutics, Inc. (VYGR) Q3 2026 10-Q Quarterly Report

Short answer

Voyager Therapeutics, Inc. (VYGR) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (down 70.0% year over year) with net income of −$25M.

Q3 2026 key financials · XBRL

Revenue
$4M
−70.0% YoY · +26.8% QoQ
Net income
−$25M
+11.5% YoY · −0.9% QoQ
Operating margin
-658.2%
EPS (diluted)
−$0.40
+14.9% YoY · +0.0% QoQ

Source: XBRL data from the Voyager Therapeutics, Inc. (VYGR) Q3 2026 10-Q on SEC EDGAR. USD.

Voyager Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $4.0M, down from $13.4M YoY, a $9.4M decrease
  • Net loss $24.7M vs $27.9M YoY, operating expenses $30.4M vs $44.0M
  • Best line: Novartis collaboration revenue $3.1M, worst: Neurocrine revenue $0.5M vs $11.1M YoY
  • Operating cash use $78.9M through September, cash, equivalents and securities $132.1M
  • Runway into Q2 2028, VY1706 dosing expected in coming months, acute safety data anticipated Q1 2027

Risk Factors

  • No material risk-factor changes identified; filing references carried-forward 10-K risks
  • Clinical development risk: VY1706 trial expected to enroll up to 18 patients across three cohorts
  • Regulatory risk: FDA-cleared VY1706 IND, but clinical dosing remains subject to enrollment timing
  • Collaboration concentration risk: nine-month collaboration revenue fell to $9.8 million from $25.0 million
  • Liquidity risk: cash, cash equivalents and marketable securities totaled $132.1 million, expected to fund operations into second quarter 2028

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Voyager Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.